Vitro Diagnostics Inc (fka VODG)

[Potse]

db7...email promo, 510(k) application, website, Romania.....

geez, I wish at least it was one of the good pump teams lol... looks like they might be done already

guess we should have sold over .15 and rebought here

My hunch is that this may not be the last time you see a stock promotion of VODG this year. I haven't sold any shares into this spike yet, because of a tidbit of information that was disclosed in the 10Q last month. VODG hired a new marketing firm in January/February, and its job over the following 6 months is to design/implement a new website for VODG and improve the companies online investment/business presence. The hiring of this new firm and this spike in share price could be completely unrelated, but my guess is that this new firm will bring more market awareness of VODG either directly or indirectly. I'm looking forward to seeing what the new website looks like......

On February 7, 2012, the Company’s board of directors ratified the terms of a consulting agreement dated January 24, 2012 with a marketing firm to provide certain public and investor relations services. The agreement has an initial six-month term and may be terminated by either party upon a material breech of the agreement. It includes several phases for which the consultant shall be compensated upon completion. The initial phase includes the completion of various strategies for which the consultant received cash compensation of $5,000 and 120,000 of the Company’s common stock, which was valued at $4,800 as discussed above. Phases II & III includes certain services regarding the Company’s online efforts, including the design and implementation of a more robust Company website, and positioning the Company as a potential investment and supplier of stem cell products within select social media. The consultant will be entitled to additional compensation for completion of Phases II & III of approximately $12,000 payable in cash or a combination of cash and common stock to be determined by the Company upon completion. For the three months ended January 31, 2012 a total of $9,800 consisting of the initial cash payment and common stock issued was charged to operations.

I have actually been semi-expecting to see momentum groups/traders become involved with VODG sometime this year as the share price continued to linger around that 5-10 cent area. IHUB investors/traders seem to take a liking toward "low-priced" 510(k) application/clearance plays, and depending on what progress VODG makes toward its 510(k) filing for its clinical grade MSC-Gro Media, VODG will probably attract some attention.

This email promo is somewhat interesting because it completely ignores what is arguably one of the easiest and most obvious aspects of VODG that could be exploited/promoted by anyone wishing to promote the stock --- the possibility of a 510(k) application. I'm not really sure why the writer of that promo did not mention/focus on the 510(k) and "seize the opportunity". Maybe it is being saved for a future email or for another group to promote.

Between the statements in the last 10-K and the last press release, I would guess there will be some information/updates at some point during the next 1-3 months on the company's progress toward a 510(k) application.........

10-K, filed in February 2012: Our stem cell products including cell lines, their derivatives and media for stem cell growth and differentiation are Class I Medical Devices and do not require FDA-pre-market approval. However, we are expanding our stem cell media product line to include media for clinical applications. In the US, these products require the filing and approval of Form 510K with the FDA. This filing provides evidence for substantial equivalence of the medical device with a previously approved device manufactured by another firm. We intend to pursue such filings for our clinical grade stem cell media during 2012. The Company has previously filed several 510K requests and gained approval of diagnostic devices. Also, we must register with the FDA as a Class II Medical Device manufacturer and are then subject to GMP inspections by the agency. Such inspections require compliance with cGMP (current good manufacturing) guidelines that stipulate control of traceable manufacturing procedures, including independence of manufacturing and quality control as well as several other provisions. The Company has operated to the cGMP standard previously and been subject to cGMP inspections by the FDA. The Company intends to comply with all regulations necessary to reach this standard.

Last press release (3/20/2012): Vitro Biopharma will present the current status of its clinical grade MSC-Gro™ Brand of culture medium for growth and differentiation of MSCs at the ISCT meeting. Through its extensive research and experience with cell culture media, Vitro Biopharma has developed highly competitive media that is suitable for clinical applications. Critical characteristics are that they are serum-free, chemically-defined and free from animal-derived components. Furthermore, it is essential that serum-free media perform the same as formulations containing contain blood serum, a complex mixture of biologically active components with intrinsic variability from batch to batch and safety issues regarding potential infectious agents. Vitro will present its results regarding each of these points and the status of FDA approval of its clinical products.


Romania: This mesenchymal stem cell research project report in Fiziologia (a Romanian medical journal) started showing up in Google scans within the last few weeks. VODG's stem cells were used in this research project, titled "COMPARATIVE ANALYSIS OF BONE MARROW-DERIVED MESENCHYMAL STEM CELLS AND IMMORTALIZED MESENCHYMAL CELL LINE".

Vitro Biopharma is mentioned on page 11......

The cells were processed no longer than 4 hours after bonemarrow harvesting. In parallel, human MSC line was obtained from Vitro BioPharma (Native Human MSC, CO, USA).

http://webcache.googleusercontent.com/search?q=cache:Oz0UZMmob3cJ:revista_fiziologia.umft.ro/archives/fiziologia2011_4.pdf+&cd=1&hl=en&ct=clnk&gl=us

As far as I am aware, VODG doesn't disclose which companies/projects use VODG's products. So Google searches are probably the best way of discovering some of that information. Back in 2010, Google showed that Vitro Biopharma's product(s) had been used by Aubrey, Inc......

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=54963803